Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?

被引：0
|
作者：
Kubilay Karaboyun
Eyyup Cavdar
Yakup Irıagac
Abdussamet Celebı
Tanju Kapagan
Ilkay Gulturk
Ozden Demır
Okan Avcı
Erdogan Selcuk Seber
机构：
[1] Tekirdag Namik Kemal University,Department of Medical Oncology, School of Medicine
[2] Marmara University,Department of Medical Oncology, School of Medicine
[3] Basaksehir Cam and Sakura City Hospital,Department of Medical Oncology
[4] Bakirkoy Dr. Sadi Konuk Training and Research Hospital,Department of Medical Oncology
[5] Ondokuz Mayıs University,Department of Medical Oncology, School of Medicine
来源：
Supportive Care in Cancer | 2023年 / 31卷
关键词：
Urinary Incontinence; Early breast cancer; Adjuvant hormone therapy; Tamoxifen; Aromatase inhibitor; ICIQ-UI SF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer
    Kudchadkar, R
    O'Regan, RM
    CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (03) : 145 - 163
  • [32] Compliance and persistence of tamoxifen and aromatase inhibitors in breast cancer patients
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 96 - 97
  • [33] Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
    Lambertini, Matteo
    Viglietti, Giulia
    de Azambuja, Evandro
    ESMO OPEN, 2018, 3 (03)
  • [34] The use of aromatase inhibitors in adjuvant therapy for early breast cancer
    Jonat, W
    Hilpert, F
    Maass, N
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (Suppl 1) : S32 - S38
  • [35] The use of aromatase inhibitors in adjuvant therapy for early breast cancer
    Walter Jonat
    Felix Hilpert
    Nicolai Maass
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 32 - 38
  • [36] Dextromethorphan phenotyping as a test for prediction of tamoxifen (TAM) activation in breast cancer patients receiving adjuvant hormone therapy.
    Gusella, Milena
    Bertolaso, Laura
    Pasini, Felice
    Modena, Yasmina
    Bononi, Antonio
    Fraccon, Anna Paola
    Da Corte, Donatella
    Cretella, Elisabetta
    Modonesi, Caterina
    Vastola, Francesca
    Nicolardi, Linda
    Pegoraro, Cristina
    Rosti, Giovanni
    Brunello, Antonella
    Segati, Romana
    Durante, Emilia
    Falci, Cristina
    Raiti, Concetta
    Rampello, Elvira
    Padrini, Robeto
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Cognitive complaints among Tunisian breast cancer patients receiving adjuvant aromatase-inhibitors
    Ben Abdallah, I.
    Rachdi, H.
    Dhib, D.
    Mejri, N.
    Berrazega, Y.
    El Benna, H.
    Daoud, N.
    Laabidi, S.
    Boussen, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S83 - S83
  • [38] Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors
    Guerrero-Zotano, Angel
    Muggia, Franco
    CURRENT CANCER THERAPY REVIEWS, 2010, 6 (01) : 51 - 61
  • [39] Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors
    Ranger, GS
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2005, 30 (04) : 313 - 317
  • [40] Adjuvant therapy for premenopausal patients with early breast cancer
    Kurebayashi, Junichi
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2008, 20 (01) : 51 - 54
12345